Here, we show that in an immunogenic mouse model, HIF-2α inhibition enhances the efficacy of ICB comprised of αPD-1 and αTIM-3, emphasizing the value of combining therapies targeting distinct pathways to overcome glioma progression. This evidence concerns the gene EPAS1 and glioma.